Skip to main content
Erschienen in: Heart Failure Reviews 2/2012

01.03.2012

Can we prevent or treat renal dysfunction in chronic heart failure?

verfasst von: Daniela Dobre, Patrick Rossignol, Marco Metra, Faiez Zannad

Erschienen in: Heart Failure Reviews | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

We aimed to summarize the predictors of renal dysfunction and present strategies to prevent and/or treat renal dysfunction in Chronic Heart Failure (CHF). Several factors may predict renal dysfunction in CHF, including older age, comorbidities (anemia, hypertension, diabetes), severity of underlying heart disease (systolic and diastolic dysfunction, central venous pressure) as well as certain therapies in specific circumstances (diuretics, nonsteroid acute inflammatory drugs, and renine-angiotensin-aldosterone (RAAS) inhibitors). Thus, prevention of renal dysfunction is possible in CHF by treating comorbidities and underlying heart disease as well as by monitoring therapies with potential toxic renal effect. At present, there is no specific treatment for renal dysfunction, but several new entities are under investigation. In conclusion, prevention of renal dysfunction is possible in CHF, but treatment is still under investigation. New studies are necessary to establish whether a specific algorithm may be used to prevent renal dysfunction in CHF patients.
Literatur
1.
Zurück zum Zitat Perrone RD, Madias NE, Levey AS (1992) Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 38:1933–1953PubMed Perrone RD, Madias NE, Levey AS (1992) Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 38:1933–1953PubMed
3.
Zurück zum Zitat Sawicki PT, Berger M (1994) Measuring progression of diabetic nephropathy. Eur J Clin Invest 24:651–655PubMedCrossRef Sawicki PT, Berger M (1994) Measuring progression of diabetic nephropathy. Eur J Clin Invest 24:651–655PubMedCrossRef
4.
Zurück zum Zitat Smilde TD, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL (2006) Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 114:1572–1580PubMedCrossRef Smilde TD, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL (2006) Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 114:1572–1580PubMedCrossRef
5.
Zurück zum Zitat Dobre D, DeJongste MJ, Lucas C, Cleuren G, van Veldhuisen DJ, Ranchor AV, Haaijer-Ruskamp F (2007) Effectiveness of beta-blocker therapy in daily practice patients with advanced chronic heart failure; is there an effect-modification by age? Br J Clin Pharmacol 63:356–364PubMedCrossRef Dobre D, DeJongste MJ, Lucas C, Cleuren G, van Veldhuisen DJ, Ranchor AV, Haaijer-Ruskamp F (2007) Effectiveness of beta-blocker therapy in daily practice patients with advanced chronic heart failure; is there an effect-modification by age? Br J Clin Pharmacol 63:356–364PubMedCrossRef
6.
Zurück zum Zitat McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW (2004) Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 109:1004–1009PubMedCrossRef McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW (2004) Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 109:1004–1009PubMedCrossRef
7.
Zurück zum Zitat Al-Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Levey AS, Sarnak MJ (2001) Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38:955–962PubMedCrossRef Al-Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Levey AS, Sarnak MJ (2001) Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38:955–962PubMedCrossRef
8.
Zurück zum Zitat Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, Hampton JR, van Veldhuisen DJ (2000) Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102:203–210PubMed Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, Hampton JR, van Veldhuisen DJ (2000) Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102:203–210PubMed
9.
Zurück zum Zitat Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, de Zeeuw D, Pocock S, van Veldhuisen DJ (2006) Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113:671–678PubMedCrossRef Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, de Zeeuw D, Pocock S, van Veldhuisen DJ (2006) Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113:671–678PubMedCrossRef
10.
Zurück zum Zitat Cauthen CA, Lipinski MJ, Abbate A, Appleton D, Nusca A, Varma A, Goudreau E, Cowley MJ, Vetrovec GW (2008) Relation of blood urea nitrogen to long-term mortality in patients with heart failure. Am J Cardiol 101:1643–1647PubMedCrossRef Cauthen CA, Lipinski MJ, Abbate A, Appleton D, Nusca A, Varma A, Goudreau E, Cowley MJ, Vetrovec GW (2008) Relation of blood urea nitrogen to long-term mortality in patients with heart failure. Am J Cardiol 101:1643–1647PubMedCrossRef
11.
Zurück zum Zitat Heywood JT, Elatre W, Pai RG, Fabbri S, Huiskes B (2005) Simple clinical criteria to determine the prognosis of heart failure. J Cardiovasc Pharmacol Ther 10:173–180PubMedCrossRef Heywood JT, Elatre W, Pai RG, Fabbri S, Huiskes B (2005) Simple clinical criteria to determine the prognosis of heart failure. J Cardiovasc Pharmacol Ther 10:173–180PubMedCrossRef
12.
Zurück zum Zitat Schrier RW (2008) Blood urea nitrogen and serum creatinine: not married in heart failure. Circ Heart Fail 1:2–5PubMedCrossRef Schrier RW (2008) Blood urea nitrogen and serum creatinine: not married in heart failure. Circ Heart Fail 1:2–5PubMedCrossRef
13.
Zurück zum Zitat Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, EKnoyan G (2005) Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (kdigo). Kidney Int 67:2089–2100PubMedCrossRef Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, EKnoyan G (2005) Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (kdigo). Kidney Int 67:2089–2100PubMedCrossRef
14.
Zurück zum Zitat Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL, Granger CB, Swedberg K, Pfeffer MA, Yusuf S, McMurray JJ (2009) Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 374:543–550PubMedCrossRef Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL, Granger CB, Swedberg K, Pfeffer MA, Yusuf S, McMurray JJ (2009) Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 374:543–550PubMedCrossRef
15.
Zurück zum Zitat McCullough PA (2003) Why is chronic kidney disease the “Spoiler” for cardiovascular outcomes? J Am Coll Cardiol 41:725–728PubMedCrossRef McCullough PA (2003) Why is chronic kidney disease the “Spoiler” for cardiovascular outcomes? J Am Coll Cardiol 41:725–728PubMedCrossRef
16.
Zurück zum Zitat Pannarale G, Carbone R, Del Mastro G, Gallo C, Gattullo V, Natalicchio L, Navarra A, Tedesco A (2010) The aging kidney: structural changes. J Nephrol 23(Suppl 15):S37–S40PubMed Pannarale G, Carbone R, Del Mastro G, Gallo C, Gattullo V, Natalicchio L, Navarra A, Tedesco A (2010) The aging kidney: structural changes. J Nephrol 23(Suppl 15):S37–S40PubMed
17.
Zurück zum Zitat Bakris GL, Weir MR (2000) Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 160:685–693PubMedCrossRef Bakris GL, Weir MR (2000) Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 160:685–693PubMedCrossRef
18.
Zurück zum Zitat Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K (2008) Esc guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the european society of cardiology. Developed in collaboration with the heart failure association of the esc (hfa) and endorsed by the european society of intensive care medicine (esicm). Eur J Heart Fail 10:933–989PubMedCrossRef Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K (2008) Esc guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the european society of cardiology. Developed in collaboration with the heart failure association of the esc (hfa) and endorsed by the european society of intensive care medicine (esicm). Eur J Heart Fail 10:933–989PubMedCrossRef
19.
Zurück zum Zitat Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589PubMedCrossRef Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589PubMedCrossRef
20.
Zurück zum Zitat Dobre D, Lambers Heerspink H, de Zeeuw D (2009) Reducing cardiovascular risk: protecting the kidney. Eur Heart J Suppl 11(Supplement F):F39–F46 Dobre D, Lambers Heerspink H, de Zeeuw D (2009) Reducing cardiovascular risk: protecting the kidney. Eur Heart J Suppl 11(Supplement F):F39–F46
21.
Zurück zum Zitat Capes SE, Gerstein HC, Negassa A, Yusuf S (2000) Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction. Diabetes Care 23:377–380PubMedCrossRef Capes SE, Gerstein HC, Negassa A, Yusuf S (2000) Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction. Diabetes Care 23:377–380PubMedCrossRef
22.
Zurück zum Zitat Knight EL, Glynn RJ, McIntyre KM, Mogun H, Avorn J (1999) Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (solvd). Am Heart J 138:849–855PubMedCrossRef Knight EL, Glynn RJ, McIntyre KM, Mogun H, Avorn J (1999) Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (solvd). Am Heart J 138:849–855PubMedCrossRef
23.
Zurück zum Zitat Waeber B (2006) Managing hypertension in high-risk patients: lessons and promises from the strathe and advance trials. J Hypertens Suppl 24:S19–S27PubMedCrossRef Waeber B (2006) Managing hypertension in high-risk patients: lessons and promises from the strathe and advance trials. J Hypertens Suppl 24:S19–S27PubMedCrossRef
24.
Zurück zum Zitat Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O’Connor CM, She L, Stough WG, Yancy CW, Young JB, Fonarow GC (2006) Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296:2217–2226PubMedCrossRef Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O’Connor CM, She L, Stough WG, Yancy CW, Young JB, Fonarow GC (2006) Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296:2217–2226PubMedCrossRef
25.
Zurück zum Zitat Ljungman S, Kjekshus J, Swedberg K (1992) Renal function in severe congestive heart failure during treatment with enalapril (the cooperative north scandinavian enalapril survival study [consensus] trial). Am J Cardiol 70:479–487PubMedCrossRef Ljungman S, Kjekshus J, Swedberg K (1992) Renal function in severe congestive heart failure during treatment with enalapril (the cooperative north scandinavian enalapril survival study [consensus] trial). Am J Cardiol 70:479–487PubMedCrossRef
26.
Zurück zum Zitat Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, van der Meer P (2008) Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 52:818–827PubMedCrossRef Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, van der Meer P (2008) Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 52:818–827PubMedCrossRef
27.
Zurück zum Zitat van der Meer P, van Veldhuisen DJ (2009) Anaemia and renal dysfunction in chronic heart failure. Heart 95:1808–1812PubMedCrossRef van der Meer P, van Veldhuisen DJ (2009) Anaemia and renal dysfunction in chronic heart failure. Heart 95:1808–1812PubMedCrossRef
28.
Zurück zum Zitat Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019–2032PubMedCrossRef Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019–2032PubMedCrossRef
29.
Zurück zum Zitat Toblli JE, Lombrana A, Duarte P, Di Gennaro F (2007) Intravenous iron reduces nt-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 50:1657–1665PubMedCrossRef Toblli JE, Lombrana A, Duarte P, Di Gennaro F (2007) Intravenous iron reduces nt-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 50:1657–1665PubMedCrossRef
30.
Zurück zum Zitat Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361:2436–2448PubMedCrossRef Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361:2436–2448PubMedCrossRef
31.
Zurück zum Zitat Ronco C, Haapio M, House AA, Anavekar N, Bellomo R (2008) Cardiorenal syndrome. J Am Coll Cardiol 52:1527–1539PubMedCrossRef Ronco C, Haapio M, House AA, Anavekar N, Bellomo R (2008) Cardiorenal syndrome. J Am Coll Cardiol 52:1527–1539PubMedCrossRef
32.
Zurück zum Zitat Verma A, Anavekar NS, Meris A, Thune JJ, Arnold JM, Ghali JK, Velazquez EJ, McMurray JJ, Pfeffer MA, Solomon SD (2007) The relationship between renal function and cardiac structure, function, and prognosis after myocardial infarction: the valiant echo study. J Am Coll Cardiol 50:1238–1245PubMedCrossRef Verma A, Anavekar NS, Meris A, Thune JJ, Arnold JM, Ghali JK, Velazquez EJ, McMurray JJ, Pfeffer MA, Solomon SD (2007) The relationship between renal function and cardiac structure, function, and prognosis after myocardial infarction: the valiant echo study. J Am Coll Cardiol 50:1238–1245PubMedCrossRef
33.
Zurück zum Zitat Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL (2009) Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 53:582–588PubMedCrossRef Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL (2009) Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 53:582–588PubMedCrossRef
34.
Zurück zum Zitat Damman K, Voors AA, Hillege HL, Navis G, Lechat P, van Veldhuisen DJ, Dargie HJ (2010) Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. Eur J Heart Fail 12:974–982PubMedCrossRef Damman K, Voors AA, Hillege HL, Navis G, Lechat P, van Veldhuisen DJ, Dargie HJ (2010) Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. Eur J Heart Fail 12:974–982PubMedCrossRef
35.
Zurück zum Zitat Jessup M, Costanzo MR (2009) The cardiorenal syndrome: do we need a change of strategy or a change of tactics? J Am Coll Cardiol 53:597–599PubMedCrossRef Jessup M, Costanzo MR (2009) The cardiorenal syndrome: do we need a change of strategy or a change of tactics? J Am Coll Cardiol 53:597–599PubMedCrossRef
36.
Zurück zum Zitat Damman K, Navis G, Smilde TD, Voors AA, van der Bij W, van Veldhuisen DJ, Hillege HL (2007) Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 9:872–878PubMedCrossRef Damman K, Navis G, Smilde TD, Voors AA, van der Bij W, van Veldhuisen DJ, Hillege HL (2007) Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 9:872–878PubMedCrossRef
37.
Zurück zum Zitat Packer M (1988) Interaction of prostaglandins and angiotensin ii in the modulation of renal function in congestive heart failure. Circulation 77:I64–73PubMedCrossRef Packer M (1988) Interaction of prostaglandins and angiotensin ii in the modulation of renal function in congestive heart failure. Circulation 77:I64–73PubMedCrossRef
38.
Zurück zum Zitat Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, Jafri SM, Krol WF, O’Connor CM, Schulman KA, Teo K, Warren SR (2009) Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the warfarin and antiplatelet therapy in chronic heart failure (watch) trial. Circulation 119:1616–1624PubMedCrossRef Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, Jafri SM, Krol WF, O’Connor CM, Schulman KA, Teo K, Warren SR (2009) Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the warfarin and antiplatelet therapy in chronic heart failure (watch) trial. Circulation 119:1616–1624PubMedCrossRef
39.
Zurück zum Zitat Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA (1998) Antiplatelet agents and survival: a cohort analysis from the studies of left ventricular dysfunction (solvd) trial. J Am Coll Cardiol 31:419–425PubMedCrossRef Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA (1998) Antiplatelet agents and survival: a cohort analysis from the studies of left ventricular dysfunction (solvd) trial. J Am Coll Cardiol 31:419–425PubMedCrossRef
40.
Zurück zum Zitat Frances CD, Noguchi H, Massie BM, Browner WS, McClellan M (2000) Are we inhibited? Renal insufficiency should not preclude the use of ace inhibitors for patients with myocardial infarction and depressed left ventricular function. Arch Intern Med 160:2645–2650PubMedCrossRef Frances CD, Noguchi H, Massie BM, Browner WS, McClellan M (2000) Are we inhibited? Renal insufficiency should not preclude the use of ace inhibitors for patients with myocardial infarction and depressed left ventricular function. Arch Intern Med 160:2645–2650PubMedCrossRef
41.
Zurück zum Zitat Juhlin T, Bjorkman S, Gunnarsson B, Fyge A, Roth B, Hoglund P (2004) Acute administration of diclofenac, but possibly not long term low dose aspirin, causes detrimental renal effects in heart failure patients treated with ace-inhibitors. Eur J Heart Fail 6:909–916PubMed Juhlin T, Bjorkman S, Gunnarsson B, Fyge A, Roth B, Hoglund P (2004) Acute administration of diclofenac, but possibly not long term low dose aspirin, causes detrimental renal effects in heart failure patients treated with ace-inhibitors. Eur J Heart Fail 6:909–916PubMed
42.
Zurück zum Zitat Dobre D, Haaijer-Ruskamp FM, Voors AA, van Veldhuisen DJ (2007) Beta-adrenoceptor antagonists in elderly patients with heart failure: a critical review of their efficacy and tolerability. Drugs Aging 24:1031–1044PubMedCrossRef Dobre D, Haaijer-Ruskamp FM, Voors AA, van Veldhuisen DJ (2007) Beta-adrenoceptor antagonists in elderly patients with heart failure: a critical review of their efficacy and tolerability. Drugs Aging 24:1031–1044PubMedCrossRef
43.
Zurück zum Zitat Agostoni P, Marenzi G, Lauri G, Perego G, Schianni M, Sganzerla P, Guazzi MD (1994) Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result. Am J Med 96:191–199PubMedCrossRef Agostoni P, Marenzi G, Lauri G, Perego G, Schianni M, Sganzerla P, Guazzi MD (1994) Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result. Am J Med 96:191–199PubMedCrossRef
44.
Zurück zum Zitat Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, Jaski BE, Fang JC, Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA (2007) Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 49:675–683PubMedCrossRef Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, Jaski BE, Fang JC, Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA (2007) Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 49:675–683PubMedCrossRef
45.
Zurück zum Zitat Palmer BF (2004) Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 351:585–592PubMedCrossRef Palmer BF (2004) Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 351:585–592PubMedCrossRef
46.
Zurück zum Zitat Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, Weir MR, Fink JC (2009) The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 169:1156–1162PubMedCrossRef Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, Weir MR, Fink JC (2009) The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 169:1156–1162PubMedCrossRef
47.
Zurück zum Zitat Weinberg JM, Appel LJ, Bakris G, Gassman JJ, Greene T, Kendrick CA, Wang X, Lash J, Lewis JA, Pogue V, Thornley-Brown D, Phillips RA (2009) Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med 169:1587–1594PubMedCrossRef Weinberg JM, Appel LJ, Bakris G, Gassman JJ, Greene T, Kendrick CA, Wang X, Lash J, Lewis JA, Pogue V, Thornley-Brown D, Phillips RA (2009) Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med 169:1587–1594PubMedCrossRef
48.
Zurück zum Zitat Weir MR, Maibach EW, Bakris GL, Black HR, Chawla P, Messerli FH, Neutel JM, Weber MA (2000) Implications of a health lifestyle and medication analysis for improving hypertension control. Arch Intern Med 160:481–490PubMedCrossRef Weir MR, Maibach EW, Bakris GL, Black HR, Chawla P, Messerli FH, Neutel JM, Weber MA (2000) Implications of a health lifestyle and medication analysis for improving hypertension control. Arch Intern Med 160:481–490PubMedCrossRef
49.
Zurück zum Zitat Rimmer JM, Horn JF, Gennari FJ (1987) Hyperkalemia as a complication of drug therapy. Arch Intern Med 147:867–869PubMedCrossRef Rimmer JM, Horn JF, Gennari FJ (1987) Hyperkalemia as a complication of drug therapy. Arch Intern Med 147:867–869PubMedCrossRef
50.
Zurück zum Zitat Lisy O, Huntley BK, McCormick DJ, Kurlansky PA, Burnett JC Jr (2008) Design, synthesis, and actions of a novel chimeric natriuretic peptide: Cd-np. J Am Coll Cardiol 52:60–68PubMedCrossRef Lisy O, Huntley BK, McCormick DJ, Kurlansky PA, Burnett JC Jr (2008) Design, synthesis, and actions of a novel chimeric natriuretic peptide: Cd-np. J Am Coll Cardiol 52:60–68PubMedCrossRef
51.
Zurück zum Zitat Pan S, Chen HH, Dickey DM, Boerrigter G, Lee C, Kleppe LS, Hall JL, Lerman A, Redfield MM, Potter LR, Burnett JC Jr, Simari RD (2009) Biodesign of a renal-protective peptide based on alternative splicing of b-type natriuretic peptide. Proc Natl Acad Sci USA 106:11282–11287PubMedCrossRef Pan S, Chen HH, Dickey DM, Boerrigter G, Lee C, Kleppe LS, Hall JL, Lerman A, Redfield MM, Potter LR, Burnett JC Jr, Simari RD (2009) Biodesign of a renal-protective peptide based on alternative splicing of b-type natriuretic peptide. Proc Natl Acad Sci USA 106:11282–11287PubMedCrossRef
52.
Zurück zum Zitat Navis G, de Zeeuw D, de Jong PE (1997) Ace-inhibitors: panacea for progressive renal disease. Lancet 349:1852–1853PubMedCrossRef Navis G, de Zeeuw D, de Jong PE (1997) Ace-inhibitors: panacea for progressive renal disease. Lancet 349:1852–1853PubMedCrossRef
53.
Zurück zum Zitat Jerums G, Panagiotopoulos S, Premaratne E, MacIsaac RJ (2009) Integrating albuminuria and gfr in the assessment of diabetic nephropathy. Nat Rev Nephrol 5:397–406PubMedCrossRef Jerums G, Panagiotopoulos S, Premaratne E, MacIsaac RJ (2009) Integrating albuminuria and gfr in the assessment of diabetic nephropathy. Nat Rev Nephrol 5:397–406PubMedCrossRef
54.
Zurück zum Zitat Tang WH, Van Lente F, Shrestha K, Troughton RW, Francis GS, Tong W, Martin MG, Borowski AG, Jasper S, Starling RC, Klein AL (2008) Impact of myocardial function on cystatin c measurements in chronic systolic heart failure. J Card Fail 14:394–399PubMedCrossRef Tang WH, Van Lente F, Shrestha K, Troughton RW, Francis GS, Tong W, Martin MG, Borowski AG, Jasper S, Starling RC, Klein AL (2008) Impact of myocardial function on cystatin c measurements in chronic systolic heart failure. J Card Fail 14:394–399PubMedCrossRef
55.
Zurück zum Zitat Damman K, Van Veldhuisen DJ, Navis G, Vaidya VS, Smilde TD, Westenbrink BD, Bonventre JV, Voors AA, Hillege HL (2011) Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart 96:1297–1302 Damman K, Van Veldhuisen DJ, Navis G, Vaidya VS, Smilde TD, Westenbrink BD, Bonventre JV, Voors AA, Hillege HL (2011) Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart 96:1297–1302
56.
Zurück zum Zitat Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ontarget study): a multicentre, randomised, double-blind, controlled trial. Lancet 372:547–553PubMedCrossRef Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ontarget study): a multicentre, randomised, double-blind, controlled trial. Lancet 372:547–553PubMedCrossRef
Metadaten
Titel
Can we prevent or treat renal dysfunction in chronic heart failure?
verfasst von
Daniela Dobre
Patrick Rossignol
Marco Metra
Faiez Zannad
Publikationsdatum
01.03.2012
Verlag
Springer US
Erschienen in
Heart Failure Reviews / Ausgabe 2/2012
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-011-9264-0

Weitere Artikel der Ausgabe 2/2012

Heart Failure Reviews 2/2012 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.